Evidence map›Paper›PMID 42281945›Full record

ArticleExpert review of precision medicine and drug development2025

Towards precision medicine for systemic lupus erythematosus and neuropsychiatric manifestations.

Bruna Martins de Aquino, Taίs Nitsch Mazzola, Paulo Rogério Julio, Rodrigo Marchi Silva, Samara Rosa Sepresse, Timothy Brett Niewold, Simone Appenzeller

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Expert review of precision medicine and drug development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Bruna Martins de AquinoMedical Pathophysiology Postgraduate Program, School of Medical Sciences, University of Campinas, Campinas, Brazil.
Taίs Nitsch MazzolaCenter for Investigation in Pediatrics, School of Medical Sciences, University of Campinas, Campinas, Brazil.
Paulo Rogério JulioChild and Adolescent Health Postgraduate Program, School of Medical Sciences, University of Campinas, Campinas, Brazil.
Rodrigo Marchi SilvaMedical Pathophysiology Postgraduate Program, School of Medical Sciences, University of Campinas, Campinas, Brazil.
Samara Rosa SepresseAutoimmunity Lab, School of Medical Sciences, University of Campinas, Campinas, Brazil.
Timothy Brett NiewoldHospital of Special Surgery, Department of Medicine, New York, NY, USA.
Simone AppenzellerAutoimmunity Lab, School of Medical Sciences, University of Campinas, Campinas, Brazil.ORCID 0000-0001-5075-4474

Funding

Translating oral CD11b agonist as a novel therapeutic for lupus nephritisR01DK084195 · NIDDK · UNIVERSITY OF TEXAS MED BR GALVESTON · PI VINEET GUPTA, Timothy B Niewold · 2011 to 2026
$5.7M
Functional consequences of intergenic autoimmune disease risk variantsR01AI164968 · NIAID · HOSPITAL FOR SPECIAL SURGERY · PI F. Yesim Demirci, Timothy B Niewold · 2023 to 2026
$3.4M
Development of a Synovium-on-a-Chip Microphysiological System to Interrogate Pathobiology and Enhance Precision Medicine in Rheumatoid ArthritisR21AR083247 · NIAMS · NEW YORK UNIVERSITY · PI CHEN, WEIQIANG, WAMPLER MUSKARDIN, THERESA · 2024 to 2025
$415k
NIAID NIH HHS R01 AI164968NIAMS NIH HHS R21 AR083247NIDDK NIH HHS R01 DK084195
6 · The paper itself

Abstract

Introduction: Systemic lupus erythematosus (SLE) is a multisystem disease with a heterogenous pathophysiological mechanisms that lead to a variety of clinical, immunological, and neuropsychiatric manifestations. Areas covered: In this review, we will summarize the current understanding of molecular pathways involved in SLE and neuropsychiatric manifestations, focusing on genetic and epigenetic mechanisms and the implications of these findings in differences observed in treatment response. Expert opinion: Great progress has been made in understanding the heterogeneity in SLE, which may help direct therapy. However, neuropsychiatric manifestations still are a challenge in clinical practice, and future studies are needed to identify relevant diagnostic and prognostic biomarkers.

Indexed as

Blood-brain barrier dysfunctioncentral nervous system lupusepigenetics in SLEgenetic risk factorsNeuropsychiatric systemic lupus erythematosus (NPSLE)precision medicinesystemic lupus erythematosus (SLE)treatment of NPSLE

Identifiers

PMID42281945
PMCPMC13251608

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.